Showing 1 - 2 results of 2 for search 'MEDICATION SAFETY', query time: 1.53s Refine Results
  1. 1
    Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
    “... 250 mg. The primary endpoint was safety profile. Other endpoints consisted of PK analysis, objective...”
    Get full text
    Article
  2. 2
    EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
    “... were retrospectively included to assess the antitumor activity and safety of monotherapy osimertinib...”
    Get full text
    Article
Search Tools: Get RSS Feed — Email this Search